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Background: This pilot study (ClinicalTrials.gov ID: NCT01507701) assessed the feasibility and safety of clonidine in
adolescent chronic fatigue syndrome (CFS). Specifically, we assessed clonidine dosage in relation to a) plasma
concentration levels, b) orthostatic cardiovascular responses, and c) possible adverse effects.
Findings: Five adolescent CFS patients (14–19 years old) received 50 μg clonidine twice per day during 14 days in
an open, uncontrolled design. Plasma concentration of clonidine was assayed by standard laboratory methods.
Changes in orthostatic cardiovascular responses were assessed by a 20o head-up tilt-test (HUT). Adverse effects
were mapped by a questionnaire.
After 14 days, C0 median (range) of clonidine was 0.21 (0.18-0.36) μg/L, and Cmax median (range) of clonidine was
0.41 (0.38-0.56) μg/L. Also, supine blood pressures and heart rate were lower during clonidine treatment, and the
HUT response was closer to the normal response. No serious adverse effects were registered.
Conclusion: Clonidine 50 μg BID seems to be safe enough to proceed from a pilot study to a controlled trial in a
select group of adolescents with CFS (ClinicalTrials.gov ID: NCT01040429).
Keywords: Chronic fatigue syndrome, Adolescents, Clonidine, Adverse effects, Head-up tilt test, Autonomic nervous
systemFindings
Background
Chronic Fatigue Syndrome (CFS) is a relatively common
and disabling condition among adolescents in developed
countries [1,2]. A study from 2004 reports the prevalence
among 8–17 years olds as high as 1.3 % [3]. The level of
disability varies, but a majority has long-lasting absence
from school, and is unable to participate in normal social
activities. The most disabled are permanently bedridden.
The pathophysiology of CFS remains poorly understood.
However, previous reports have documented enhanced
sympathetic nervous activity at rest and during moderate* Correspondence: brwylle@online.no
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distribution, and reproduction in any mediumsomatic stressors, affecting cardiovascular control [4]. For
instance, previous experiments at our institution have
shown higher blood pressures, heart rate and LF/HF ratio
(low-frequency:high-frequency heart rate variability ratio,
an index of sinus node sympathovagal balance derived
from spectral analyses of heart rate) at rest among adoles-
cent CFS patients as compared to healthy controls, and a
stronger increase in these variables upon orthostatic
stress, such as head-up tilt [5-7]. A detailed study of the
baroreceptor reflex suggests alterations of the central “set-
point” [8]. Similarly, ambulatory measurements of blood
pressures and heart rate indicate higher nocturnal values
among CFS patients as compared to controls [9], and
studies of neuroendocrinology report higher levels of cate-
cholamines [10]. Taken together, these findings suggest
that enhanced sympathetic nervous activity due to func-
tional alteration in the central nervous system might con-
stitute a key element of CFS pathophysiology and mightntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[11,12]. Alternatively, the autonomic alterations in CFS
might be secondary to another disease mechanism, such
as hypovolemia [13]. However, important characteristics
of the cardiovascular responses among CFS patients does
not support this possibility, as has been thoroughly dis-
cussed elsewhere [8,11].
To date, only cognitive behavioral therapy and graded
exercise therapy have a well-documented beneficial effect
in the treatment of CFS [2,14]. Thus, searching for a
pharmacological therapy should have high priority, and
the documented enhancement of sympathetic nervous
activity represents a possible target for intervention. Cloni-
dine is an agonist to the adrenergic, inhibitory α2-receptor.
It has a general inhibitory influence on sympathetic
nervous activity, in particular due to its effect in the cen-
tral nervous system, resulting in lower blood pressures
and heart rate [15]. Therefore, clonidine might be a poten-
tially useful therapy in CFS. To our knowledge, no prior
study of clonidine in CSF has been undertaken. In a trial
of this drug, the well-known alteration of cardiovascular
control in CFS patients might serve as a biomarker.
An area of concern, however, is the possibility of adverse
effects. In fact, clonidine might worsen rather than im-
prove the orthostatic intolerance among CFS patients, in-
creasing the risk of syncope; this is particularly true if the
autonomic alterations are secondary to hypovolemia ra-
ther than a primary disease mechanism. Also, CFS
patients are generally considered to be sensitive towards
adverse pharmacological effects, maybe because of altered
pharmacodynamics [14]. Therefore, a pilot study assessing
feasibility and safety of clonidine therapy is necessary prior
to a large-scale trial. Of note, recent randomized con-
trolled trials reported a beneficial effect of clonidine and
low risk of side-effects in pediatric attention deficit/hyper-
activity disorder (AD/HD) and tic disorders [16,17]. Also,
in pediatric practice, clonidine is used for analgesic pur-
poses, to alleviate abstinence responses, and against spasti-
city [18,19].
The Norwegian Study of Chronic Fatigue Syndrome in
Adolescents: Pathophysiology and Intervention Trial
(NorCAPITAL) is a randomized, placebo-controlled,
double-blind trial of clonidine in adolescent CFS (Clini-
calTrials.gov ID: NCT01040429). The aim of this pilot
study (ClinicalTrials.gov ID: NCT01507701) was to in-
vestigate the feasibility and safety of clonidine in adoles-
cent CFS. Specifically, we wanted to assess appropriate
dosage in relation to a) plasma concentration levels, b)
orthostatic cardiovascular responses, and c) reports of
possible adverse effects, in particular syncope.
Patients
Five adolescent CSF patients were recruited from the
Pediatric outpatient clinic, Oslo University Hospital,Rikshospitalet, Norway, which serves as a national refer-
ral center for children and adolescents with unexplained
chronic fatigue. Other disease states that might explain
their present symptoms, such as autoimmune, endo-
crine, neurologic or psychiatric disorders (including de-
pression and anxiety), were ruled out by a thorough and
standardized set of investigations.
Different case definitions of CFS exist. The frequently
used definition from the International Chronic Fatigue
Syndrome Study Group (commonly referred to as the
Fukuda-definition) requires at least six months of unex-
plained chronic or relapsing fatigue of new onset, se-
verely affecting daily activities, as well as four or more of
eight specific accompanying symptoms (headache,
muscle pain, joint pain, sore throat, tender lymph nodes,
impaired memory or concentration, unrefreshing sleep,
and malaise after exertion) [20]. The validity of this def-
inition has been questioned [21]. Therefore, in this
study, three consecutive months of unexplained disab-
ling fatigue and no accompanying symptoms were
required for inclusion. This approach is in line with the
clinical recommendations from The Royal College of
Paediatrics and Child Health [2] and the National Insti-
tute for Health and Clinical Excellence [14], and is also
proven feasible in previous studies from our group
[5,10].
Exclusion criteria included supine systolic blood pres-
sure (SBP) < 85 mm Hg, a fall in SBP upon standing >
30 mm Hg, supine heart rate (HR) < 50 beats/min, ab-
normal ECG, permanent bed-rest, regular use of phar-
maceuticals, other chronic diseases and a positive
pregnancy test.
Study protocol
Patients were invited to two clinical encounters at our
institutions, separated by a time period of 14 days. At
the first encounter, a head-up tilt-test was performed.
The subjects were positioned horizontally on a-table
with foot-board support (Model 900–00, CNS-systems
Medizintechnic, Graz, Austria) and attached to the Task
Force MonitorW (Model 3040i, CNSystems Medizintech-
nic, Graz, Austria), a device for non-invasive recording
of cardiovascular variables [22]. We obtained a 5 minute
baseline recording before tilting head-up to 20° over 10
seconds and maintaining that position for 15 minutes,
followed by another 5 minutes epoch in the horizontal
position. Instantaneous heart rate (HR) was obtained
from the R-R interval of the electrocardiogram; each R
deflection was automatically detected by the Task Force
Monitor software. In addition, the RR-interval was sub-
jected to spectral analysis using an adaptive autoregres-
sive algorithm, calculating spectral power densities in
the low-frequency (LF) band (0.04-0.15 Hz) and the
high-frequency (HF) band (0.15-0.4 Hz). These indices
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HF-ratio is a measure of “sympathovagal balance”, where
higher values indicate enhanced sympathetic activity.
Photoplethysmography on the right middle finger was
used to obtain a non-invasive, continuous recording of
arterial blood pressure, and impedance cardiography was
used to obtain a continuous recording of the stroke vol-
ume. All recorded signals were on-line transferred to the
built-in recording computer of the Task Force MonitorW,
running software for real-time data acquisition. Immedi-
ately after the tilt test, subjects were given 50 μg cloni-
dine orally. During the next 5 hours, they were
monitored with repeated blood samples for clonidine
concentration assays.
The participants were instructed to take 50 μg cloni-
dine twice per day (BID) until the second clinical en-
counter, which consisted of blood samples (for assays of
clonidine concentration) and a repeated head-up tilt test.
Also, participants were questioned about possible side-
effects of clonidine treatment (such as sleepiness, consti-
pation, dizziness, syncope and dry mucus membranes).
At discharge from the second clinical encounter, they
were instructed to take 25 μg clonidine BID for another
week, after which the treatment was discontinued.
Two days in advance of both encounters, all partici-
pants were instructed not to drink beverages containing
alcohol or caffeine, not to take any drugs, and not to use
tobacco products. They were requested to fast overnight
prior to the first clinical encounter, and apply an oint-
ment of the local anesthetic lidocaine (EmlaW) in the
antecubital fossa one hour before venous puncture.
Blood samples and HUT were carried out between 8
and 10 am at both occasions in a quiet, warm room.
Written, informed consent was obtained from all par-
ticipants and their parents. The study was approved by
the Regional committee for ethics in medical research
(REK Sør-st C) and The Norwegian Medicines Agency.Table 1 Population characteristics and clonidine
concentration at steady state
Number (male/female) 5 (3/2)
Median (range)
Age (years) 14
(14–19)
BMI (kg/m2) 20.8
(17.0-22.4)
Disease duration (months) 34
(27–48)
C0 of clonidine (μg/L), 0.21
(0.18-0.36)
Cmax of clonidine (μg/L) 0.41
(0.38-0.56)
BMI=body mass index.Laboratory procedures
The blood samples for clonidine determinations were
collected in 4 mL heparin tubes. After centrifugation for
12 minutes at 1000 g at room temperature, the plasma
fraction was frozen at −20°C until analysis within 2
weeks. Plasma concentrations of clonidine were assayed
by the method of Müller et al. with some modifications
[23]. The samples were separated on an Alliance HT
2795 HPLC system and detected by a Micromass Quat-
tro micro API MS/MS-instrument (Waters, Milford,
MA). The MS/MS conditions were optimized by manual
tuning during pump-infusion of neat solutions. Due to
the low dose of clonidine used in this study, the high
end of the calibration range was omitted. Calibrated
range was from 0.10 μg/L to 5.00 μg/L. The intra assayCV was median 1.0 % at 5.00 μg/L and median 10 % at
0.10 μg/L (lower limit of quantification).Data analyses
All data were exported to Microsoft Excel for further
analyses. From each experimental run of HUT, we calcu-
lated the median of all variables in two epochs: From
270 to 30 seconds prior to tilt (Baseline) and from 30 to
270 seconds after beeing tilted (Tilt). We also computed
delta values (Tilt – Baseline). Cardiac output was com-
puted as stroke volume times HR, whereas total periph-
eral resistance was calculated as mean arterial blood
pressure (MBP) divided by cardiac output. Relevant
hemodynamic variables were indexed against body sur-
face area. This method of analyzing results from HUT
has successfully been used in previous projects from our
institution [5,6].
Results are displayed as median and total range. Due
to the low number of participants, we did not carry out
statistical tests.Results
Five patients (three males and two females, median age
14 years, median disease duration 34 months) were
screened; they all adhered to the inclusion and exclusion
criteria, and were therefore enrolled in the project
(Table 1). All patients had a high level of school absen-
teeism, but no one was permanently bed-ridden.
After the initial, single oral dose of 50 μg clonidine,
plasma concentration levels rose to a maximum level
after 60 – 120 minutes (Tmax) in all patients; median
(range) value was 0.26 (0.14 - 0.29) μg/L. After 14 days
of clonidine treatment, median trough concentration
(C0) was 0.21 μg/L, rising to a median level of 0.41 μg/L
(Cmax) two hours after administration of the regular dose
(Table 1).
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dian HR, MBP, DBP and SI at baseline during clonidine
treatment (Table 2). At tilt, blood pressures tended to
decrease rather than increase during clonidine treat-
ment, whereas the increase in TPRI and LF/HF was less
pronounced.
No serious adverse effects were registered during the
treatment period (Table 3). Initially, all patients reported
a feeling of dry eyes and two reported a feeling of dry
mouth; these symptoms subsided after a few days. Three
of the patients reported a change in sleeping pattern;
one reported lighter sleep, one uneasy sleep, and one
better sleep. Also, one patient reported sleepiness at day-
time. One patient experienced increased fatigue, and one
patient described slight dizziness.
Discussion
This pilot study indicates that 50 μg clonidine BID
might be safe in the treatment of adolescent CFS. The
plasma concentration levels were adequate, the ortho-
static responses were closer to the normal responses,
and the therapy was well tolerated by the patients with
no serious side effects.
The pharmacokinetics and antihypertensive effects of
low dose clonidine treatment have been studied among
adult hypertensive patients [24]. Applying a dosage of 75
μg clonidine bd during 5 days, mean Cmax and Tmax
were reported to be 0.65 μg/L and 2.5 hrs, respectively,
corresponding neatly with our results. Also, a slight, butTable 2 Hemodynamic variables before and during clonidine
(baseline) and the response (Δ) to 20 deg. head-up tilt-test
Baseline
Before clonidine During
HR (beats/min) 69.5 65.4
(63.1-107.1) (59.5-88
SBP (mm Hg) 101.8 101.2
(91.0-104.9) (96.2-10
MBP (mm Hg) 76.1 74.0
(65.4-76.1) (68.9-80
DBP (mm Hg) 62.1 59.1
(53.5-70.6) (57.4-64
SI (ml/m2) 50.4 42.7
(32.1-62.2) (34.6-78
CI (l/min/m2) 3.4 3.0
(3.3-3.9) (2.5-4.7)
TPRI (mm Hg/l/min/m2) 9.0 9.0
(6.3-9.6) (5.2-13.2
LF/HF 0.56 0.57
(0.30-0.93) (0.38-0.6
HR=heart rate; SBP=systolic blood pressure; MBP=mean arterial blood pressure; DBP
peripheral resistance index; LF/HF=low-frequency:high-frequency heart rate variabilsignificant antihypertensive effect was found, in line with
our data. Other studies report that a plasma concentra-
tion of 0.2 – 2.0 μg/L of clonidine is associated with
clinical effects [25,26]; in this study, the plasma concen-
trations of clonidine in all individuals were within this
range, but in the lower end.
In CFS patients, orthostatic challenges cause a stron-
ger increase in HR, blood pressures, TPRI and LF/HF as
compared to healthy controls [5,6]. In this study, after
clonidine treatment, blood pressure values tended to de-
crease rather than increase, and the increase in TPRI
and LF/HF was less pronounced. Thus, clonidine seems
to normalize the head-up tilt-test responses. Similar
results were found in adult patients with ulcerative col-
itis treated with clonidine [15]. Previously, we have sug-
gested that the abnormal cardiovascular responses
during orthostatic challenges in CFS patients are con-
nected with a key feature of the underlying pathophysi-
ology [11]. We therefore speculate that clonidine not
only might improve cardiovascular control, but also
might have a beneficial effect on fatigue and functional
ability in adolescent CFS. This hypothesis should be
tested in a standard randomized controlled trial, in
which the head-up tilt-test might serve as a biomarker.
The patients’ reports of dry mucus membranes, altered
sleeping pattern, and slight dizziness are well known
side-effects of clonidine [27]. However, sleeping difficul-
ties and dizziness might also represent natural fluctu-
ation of CFS symptom intensity, and should nottreatment. Median (range) values at supine rest
Δ (Tilt - Baseline)
clonidine Before clonidine During clonidine
1.7 1.4
.0) (−0.1-4.4) (−1.0-6.7)
0.9 −1.5
7.4) (−10.4-5.1) (−5.7-9.0)
2.5 −2.0
.8) (−9.5-5.6) (−3.7-2.0)
4.0 −2.8
.0) (−9.4-4.6) (−3.2-0.8)
−4.8 −3.4
.2) (−6.0–2.8) (−8.2–1.3)
−0.3 −0.1
(−0.3-0.0) (−0.4-0.0)
0.8 0.3
) (−0.3-1.6) (−0.1-1.1)
0.58 0.36
4) (−0.05-0.82) (−0.01-0.68)
=diastolic blood pressure; SI=stroke index; CI=cardiac index; TPRI=total
ity ratio.
Table 3 Reported adverse effects of clonidine during the treatment period
Dry mucus
membranes (eyes/mouth)
Lighter/uneasy
sleep
Heavier
sleep
Sleepiness
at daytime
Increased
fatigue
Dizziness
Patient #1 x x x
Patient #2 x x
Patient #3 x x
Patient #4 x x
Patient #5 x x
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increased fatigue – reported by one patient – might rep-
resent an adverse effect which is of particular concern in
patients with CFS; however, increased fatigue might
equally well stem from alterations of disease activity.
These uncertainties should be specifically addressed in a
randomized controlled trial. Given the orthostatic in-
tolerance of CFS, we were concerned that clonidine
treatment might provoke syncope in this patient group.
However, syncope was not experiences by any of the
participants in this study, nor was there any large reduc-
tion of blood pressures during tilt. The low dosages,
yielding plasma concentration within the lower range of
what is considered clinically effective, probably contribu-
ted to low incidence of side-effects. This might be par-
ticularly important in CFS patients, which are often
considered to be particularly sensitive towards adverse
pharmacological effects [14].
Study limitations
We did not estimate the frequency of syncope or other
adverse effects prior to this study; nor did we perform a
power calculation. To the best of our knowledge, cloni-
dine has never been subjected to a clinical trial in CFS
patients; therefore, instead of assuming anything about
effects, we found it more appropriate to conduct a
small-scale pilot study. Hypovolemia remains an alterna-
tive explanation for the autonomic alterations among
CFS patients [13]; thus measuring blood volume prior to
initiation of clonidine would have would have been in-
formative and also improved study safety. Generally, the
small number of participants and the open-label, uncon-
trolled design of this study do not allow firm conclusion.
Conclusions
Clonidine 50 μg BID seems to be safe enough to proceed
from a pilot study to a controlled trial in a select group
of adolescents with CFS (ClinicalTrials.gov ID:
NCT01040429).
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